Abstract. We reported previously that intracerebroventricular (i.c.v.) administration of P2X-receptor agonists produced antinociception and the effect was attenuated by i.c.v. pretreatment with b 2 -adrenergic receptor antagonists. The present study examined the involvement of noradrenergic neurons arising from the locus coeruleus (LC) in the supraspinal antinociception by the P2X-receptor agonist a ,b-methylene-ATP in rats. We found that pretreatment with DSP-4 (50 mg / kg, i.p.), which is a neurotoxin to selectively disrupt noradrenergic neurons arising from the LC, significantly attenuated the antinociception by i.c.v. administration of a ,b -methylene-ATP (10 nmol / rat). Microinjection of a ,b-methylene-ATP (0.1 and 1 nmol / side) into the bilateral LC significantly elevated the nociceptive threshold more potently than the i.c.v. administration at a dose of 10 nmol / rat. The antinociception by intra-LC injection of a ,b -methylene-ATP (1 nmol / side) was significantly attenuated by co-injection of pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (1 nmol / side), a non-selective P2X-receptor antagonist. These results suggest that noradrenergic neurons arising from the LC are involved in the supraspinal antinociception by a ,b -methylene-ATP through P2X receptors in the LC.
Introduction
Extracellular ATP has been established as a signaling molecule that mediates diverse biological effects via P2 purinoceptors in both the peripheral (1, 2) and central nervous systems (3 -5) . P2 purinoceptors are classified into two subfamilies, ligand-gated, ionotropic P2X receptors (P2X 1-7 ) and G protein-coupled, metabotropic P2Y receptors (P2Y 1, 2, 4, 6, 11, 12 ), on the basis of their structures and signal transduction systems (6) . A body of evidence indicates that P2X receptors are involved in both peripheral and spinal pain transmission (7 -9) . Of the seven P2X receptors identified to date, at least six (P2X 1 -P2X 6 ) receptors are present in sensory ganglia, forming distinct distribution patterns in the population of sensory neurons (10, 11) . In particular, the expression of the P2X 3 receptor appears selective for a subpopulation of small-diameter dorsal root ganglion neurons, which are probably associated with nociception (12 -16) . Furthermore, an in vivo study provided the evidence that the activation of P2X receptors, especially the P2X 3 subtype, contributes to acute nociceptive behavior (17, 18) , hyperalgesia (19, 20) , and allodynia (21 -24) . These observations strongly support the idea that ATP plays a crucial role in facilitating pain transmission at the peripheral and spinal sites via the P2X receptors, although we recently reported an inhibitory role of P2Y receptors in spinal pain transmission (25, 26) .
On the other hand, at the supraspinal site, little is known about the involvement of P2X receptors in pain transmission. We previously reported that intracerebroventricular (i.c.v.) administration of ATP and P2X-receptor agonists produced mechanical and thermal antinociception in rats (27) . The antinociceptive effect was rapid and short-lasting, which was similar to the duration of peripheral or spinal P2X receptor-mediated nociceptive response or hyperalgesia (17, 19, 25) . Furthermore, we found that the supraspinal antinocicep-tion by i.c.v. a ,b-methylene-ATP was attenuated by i.c.v. pretreatment with b 2 -adrenergic receptor antagonists (28) . These findings suggest that supraspinal P2X receptors play an inhibitory role in nociceptive transmission by activation of supraspinal b 2 -adrenergic receptors. However, it remains unclear where and which noradrenergic (NA) neurons are involved in the supraspinal antinociception by a ,b-methylene-ATP.
The locus coeruleus (LC) is the largest source of NA fibers projecting to several areas of the central nervous system. It has been reported that several subtypes of P2X receptors are expressed and co-localized with tyrosine hydroxylase in the rat LC (29) . In electrophysiological studies, a ,b-methylene-ATP excited LC neurons in the rat pontine slice preparation (30 -32) . Furthermore, it was reported that ATP and noradrenaline are co-released in the LC (33) . Thus, the goal of the present study was to determine the involvement of central NA neurons arising from the LC in the supraspinal antinociception by a ,b-methylene-ATP. N-2-Chloroethyl-N-ethyl-2-bromobenzylamine (DSP-4) is an alkylating agent that causes selective disruption of NA projections especially arising from the LC (34, 35) . Systemic injection of DSP-4 produces a long-term depletion of brain NA without affecting other catecholamine-containing cell groups, while the peripheral NA depletion is transitory with recovery within days (36) . These characteristics make DSP-4 a valuable tool for investigating the role of the central NA system in behavior. Therefore, in the present study, we first examined the effect of DSP-4 pretreatment on the antinociception by i.c.v. administration of a ,b-methylene-ATP in rats. Furthermore, we directly investigated the effect of microinjection of a ,b-methylene-ATP into the LC on the nociceptive threshold.
Materials and Methods

Animals
Male Sprague-Dawley rats initially weighing 180 -250 g were used. Animals were kept at a constant ambient temperature (24 ± 1°C) under a 12-h light and dark cycle with free access to food and water. The experiments were conducted in accordance with the ethical guidelines of the Kyoto University animal experimentation committee, and the guidelines of The Japanese Pharmacological Society.
DSP-4 pretreatment and measurement of monoamine contents in brain regions
Rats were intraperitoneally injected with DSP-4 hydrochloride (Sigma, St. Louis, MO, USA) freshly dissolved in saline at a dose of 50 mg / kg or saline in a volume of 1 ml / kg body weight. Then, the rats were returned to their cages and left for at least 10 days before the experiments. The dose and time schedule were chosen on the basis of previous findings (34) .
High performance liquid chromatography with an electrochemical detection (HPLC-ECD) system was used to determine the contents of NA, dopamine (DA), and 5-hydroxytryptamine (5-HT) in the cortex, hippocampus, thalamus, and hypothalamus. After the experiments, the animals were sacrificed by decapitation and the brains were rapidly dissected. Then, they were frozen in liquid nitrogen and stored at -80°C until use. The tissues were homogenized in 0.1 N HClO 4 containing 10 mM Na 2 S 2 O 5 and 1 mM ethylenediaminetetraacetic acid (EDTA) and then placed on ice for 15 min. The homogenates were centrifuged at 30,000ǵ
for 15 min at 4°C, and the pH of the supernatants was adjusted to 3.0 with 1 M CH 3 COONa. After filtration through a 0.22-m m pore size membrane filter, a 30-ml aliquot was automatically injected into the HPLC-ECD system via the auto-sample injector (M231XL; Eicom, Kyoto). The mobile phase for measurement of monoamines consisted of 0.044 M citric acid -0.039 M sodium acetate buffer (pH 3.5) containing 230 mg / l sodium 1-octanesulfonate, 5 mg / l EDTA, and 17% methanol delivered at a constant flow rate of 0.23 ml / min using an HPLC pump (EP-300, Eicom). Monoamines were separated on a reverse phase column (Eicompak CA-5ODS, 2.1 mm i.d. ´150 mm; Eicom) and detected using an electrochemical detector (ECD-300, Eicom) with a working electrode set at +750 mV versus the Ag / AgCl reference electrode. The temperature of the column was maintained at 25°C in an oven (ATC-300, Eicom). Chromatogram peaks were analyzed by means of the PowerChrom data recording system (EPC-300, Eicom) using a computer, and the monoamine levels were calculated as pmol / mg protein wet weight tissue.
Surgical procedures and drug administration
For i.c.v. administration, under pentobarbital (50 mg / kg, i.p.) anesthesia, each rat was unilaterally implanted with a stainless steel guide cannula (o.d. 0.7 mm) above the lateral ventricle (AP -0.8 mm, L 1.5 mm, DV -2.0 mm from bregma) based on the Atlas of Paxinos and Watson (37) . The guide cannula was held firmly in place by dental acrylic cement. After surgery, the rats were individually returned to their cages and left to recover for 5 to 7 days until the following experiments. Drugs were administered via a stainless steel injection cannula (30-gauge), which was inserted immediately 5.0-mm below the surface of the skull when attached to the guide cannula, at a volume of 5 m l / rat at a constant rate of 10 m l / min. The injection cannula was left in place for an additional 1 min to prevent backflow of drugs.
For intra-LC microinjection, under pentobarbital (50 mg / kg, i.p.) anesthesia, each rat was bilaterally implanted with guide cannulae (o.d. 0.5 mm) above the LC (AP -0.8 mm, L ±1.3 mm, DV -3.0 mm from lambda). After surgery, the rats were individually returned to their cages and left to recover for 5 to 7 days until the following experiments. Drugs were bilaterally administered via stainless steel injection cannulae (33-gauge), which were inserted at 7.5-mm below the surface of the skull when attached to the guide cannulae, at a volume of 1 m l / side at a constant rate of 0.5 m l / min. The injection cannulae were left in place for an additional 2 min to prevent backflow of drugs.
Measurement of nociceptive threshold
In conscious rats, mechanical nociceptive threshold was evaluated by the paw pressure test using an analgesimeter (Ugo Basile, Milan, Italy) with a cuneate piston. The piston was put on the ventral surface of the hind paw. The pressure was loaded at a rate of 32 g / s. The pressure that elicited paw withdrawal behavior was determined as the nociceptive threshold. The procedures for the measurement were carried out three times per day for habituation. After two days of habituation, the threshold was measured following two additional habituation procedures, and the value was taken as a control. The control value of the nociceptive threshold was 143.3 ± 2.4 g (n = 96). Of these rats, the control value of the nociceptive threshold in the DSP-4-pretreated group (142 ± 3.24 g) (n = 18) showed no significant difference compared with that in the salinepretreated group (144.3 ± 3.2 g) (n = 17). Soon after measuring the control value, a ,b-methylene-ATP; pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) (Sigma), dissolved in phosphate-buffered saline (PBS); or PBS was administered intracerebroventricularly; and the value was measured at 5, 10, 20, and 30 min after the administration.
Histology
After the behavioral tests for intra-LC microinjection, histological analyses were performed. To verify the placement of each injection cannula, 1 ml of a solution of cresyl violet including thionine in PBS was infused through similar injection cannulae. The rats were sacrificed by decapitation and the brain was rapidly removed and frozen in powdered dry ice. Then, coronal sections (50 mm) including the LC were prepared on a cryostat, thaw-mounted onto gelatin-coated slides, and stored at -80°C until use. The slices were stained with cresyl violet and each section was examined by microscopy (´400).
Statistical analyses
Statistical analyses were performed by the Dunnett's or Bonferroni's post hoc multiple comparisons test following the analysis of variance (ANOVA) or the Mann-Whitney U-test. Differences at P<0.05 were considered significant.
Results
Changes of monoamine contents by DSP-4 pretreatment
The extent of neurotoxic lesions by DSP-4 pretreatment was assessed by measuring the brain regional contents of monoamines. After the behavioral tests, NA, DA, and 5-HT contents in the cortex, hippocampus, thalamus, and hypothalamus were quantified (Table 1) . DSP-4 pretreatment significantly reduced the NA contents in the cortex, hippocampus, and thalamus compared with those of the saline-pretreated rats. The effect of DSP-4 pretreatment on the NA content in the hypothalamus was also significant, although it was weaker than those in the other regions. On the other hand, DSP-4 pretreatment showed no significant effects on the DA and 5-HT contents in any brain regions examined, although it slightly reduced them.
Effect of DSP-4 pretreatment on the supraspinal antinociception by i.c.v. a ,b-methylene-ATP
In saline-pretreated rats, i.c.v. administration of PBS did not alter the mechanical nociceptive threshold, while i.c.v. administration of a ,b-methylene-ATP (10 nmol / rat) significantly elevated it. A significant elevation of the threshold was observed at 5 min after i.c.v. administration of a,b-methylene-ATP (163.6 ± 9.0% of control) compared with the group i.c.v. administered with PBS (106.0 ± 6.1% of control). The antinociceptive effect was apparently rapid and short-lasting which peaked at 5 min and disappeared within 20 min after the i.c.v. administration. The antinociceptive effect of a,b-methylene-ATP (10 nmol / rat) was attenuated by DSP-4 pretreatment. A significant attenuation by DPS-4 pretreatment was observed at 5 min after i.c.v. administration of a ,b -methylene-ATP (117.8 ± 4.2% of control) compared with the saline-pretreated group. Furthermore, in DSP-4-pretreated rats, there was no significant difference between the groups i.c.v. administered with PBS and a,b-methylene-ATP (Fig. 1) .
Histology for microinjection sites into the LC
After the tests for microinjection into the LC, histological analyses were performed. As shown in Fig. 2 , the microinjection sites of a ,b-methylene-ATP or PBS were found to be correctly placed within the LC in 35 rats from which experimental data were finally analyzed. The data of 31 rats were excluded in the final analysis because of incorrect placement of the microinjection sites.
Effect of microinjection of a ,b-methylene-ATP into the bilateral LC on the mechanical nociceptive threshold
Microinjection of a ,b-methylene-ATP (0.001 -1 nmol / side) into the bilateral LC dose-dependently elevated the mechanical nociceptive threshold, while microinjection of PBS did not alter it (Fig. 3) . Significant elevations of the threshold were observed at 5 min after the LC microinjection of a ,b-methylene-ATP at doses of 0.1 and 1 nmol / side (145.0 ± 11.9% and 217.9 ± 20.0% of the control, respectively) and at 10 min at a dose of 1 nmol / side (128.0 ± 12.5% of control), compared with the group treated with PBS (104.0 ± 5.1% and 93.7 ± 5.4% of the control, respectively). The antinociceptive effect was apparently rapid and short-lasting which peaked at 5 min and disappeared within 20 min after the microinjection. Estimated EC 50 value at 5 min after the microinjection of a ,b-methylene-ATP into the LC was 0.21 nmol / rat and 17-fold lower than that of i.c.v. administration (3.60 nmol / rat), as previously reported (27) . The antinociceptive effect of intra-LC injection of a ,b-methylene-ATP (1 nmol / side) was dose-dependently attenuated by co-injection of PPADS (0.1 and 1 nmol / side). A significant attenuation by PPADS was observed at a dose of 1 nmol / side (128.6 ± 16.3% of control) compared with a ,b-methylene-ATP alone. On the other hand, PPADS (1 nmol / side) alone did not have any significant effect on the nociceptive threshold (103.2 ± 4.57% of control) (Fig. 4) . After the behavioral tests, NA, DA, and 5-HT contents in the cortex, hippocampus, thalamus, and hypothalamus of the saline-or DSP-4 (50 mg /kg)-pretreated rats were measured. Values are presented as means of monoamine contents (pmol/mg protein) ± S.E.M. of five animals. In parentheses, means of the % of the saline-pretreated group in respective brain regions (100%) ± S.E.M. are indicated. *P<0.05, **P<0.01, compared with the saline-pretreated group (Mann-Whitney U test). 
Discussion
We previously reported that i.c.v. administration of P2X-receptor agonists produced antinociception (27) and the effect was attenuated by i.c.v. pretreatment with b 2 -adrenergic receptor antagonists in rats (28) . In the present study, we found that pretreatment with the NA neurotoxin DSP-4 attenuated the antinociception by i.c.v. administration of a ,b-methylene-ATP. It has been reported that DSP-4 treatment produces nearly complete lesions to all NA terminals which arise from the LC, while sparing fibers from other catecholamine containing cell group (38) . The findings of the present study showed a significant reduction in NA, but not in DA or 5-HT, contents in the cortex, hippocampus, thalamus, and hypothalamus. In particular, a remarkable reduction in NA contents was observed in the cortex, hippocampus, and thalamus. Since NA neurons arising from the LC are known to provide a major projection to the hippocampus, cortex, and thalamus, and also minor projections to limited areas of the hypothalamus (39), these findings suggest that DSP-4 treatment under the present condition is sufficient to preferentially disrupt NA neurons arising from the LC. DSP-4 treatment also produces the disruption of descending NA neurons that project to the spinal cord. However, intrathecal pretreatment with phentolamine and propranolol, a -and b -adrenergic receptor antagonists, respectively, had no significant effects on the antinociception by i.c.v. a,bmethylene-ATP (our unpublished data). Taken together, it is conceivable that the ascending NA neurons arising from the LC are involved in the supraspinal antinociception by a ,b-methylene-ATP.
It is known that nociceptive stimuli profoundly influence the activity of LC neurons and the release of several neurotransmitters in this brain region (40, 41) . In the present study, we directly investigated the effect of microinjection of a ,b-methylene-ATP into the bilateral LC on the mechanical nociceptive threshold and found that lower doses of a ,b-methylene-ATP (0.1 and 1 nmol / side) produced significant and transient antinociception. The effect peaked at 5 min and disappeared by 20 min after the intra-LC microinjection, which is similar with the duration of antinociception by i.c.v. administration. Nevertheless, the effectiveness of antinociception by intra-LC injection was more potent than that of i.c.v. administration. Furthermore, a nonselective P2X-receptor antagonist PPADS, significantly antagonized the antinociceptive effect of intra-LC microinjection of a ,b-methylene-ATP. These findings suggest that P2X receptors in the LC could strongly contribute to the supraspinal antinociception by a,bmethylene-ATP.
Yao et al. (29) reported widespread distribution patterns of P2X receptors and their co-localization with tyrosine hydroxylase throughout the rat brainstem including the LC. Furthermore, it has been reported that a,b-methylene-ATP excited LC neurons in the rat pontine slice preparation (30, 32) . On the other hand, we previously reported that i.c.v. pretreatment with b 2 -, but not b 1 -, adrenergic receptor antagonists significantly attenuated the antinociception by i.c.v. a ,b -methylene-ATP (28) . Taken together, it is suggested that supraspinally administered a ,b-methylene-ATP excites NA neurons arising from the LC through P2X receptors in the LC and induces the release of NA from the NA nerve terminals, and then the released NA acts on supraspinal b 2 -adrenergic receptors to produce antinociception.
In the immunohistochemical study, staining of P2X 2 and P2X 3 , but not P2X 1 , receptors were observed in the LC (29) . Since a ,b-methylene-ATP is known to be quite selective to P2X 1 , P2X 3 , and heteromeric P2X 2/ 3 receptors (42 -44), it is suggested that P2X 3 and / or heteromeric P2X 2/ 3 receptors in the LC might be involved in the supraspinal antinociception by a,bmethylene-ATP. However, P2X 4 and P2X 6 receptors are also reported to co-assemble into a novel heteromeric receptor, which is sensitive to a ,b -methylene-ATP (45) . Since both receptor subtypes are moderately expressed in the LC (29) , the involvement of the heteromeric P2X 4/ 6 receptor in the LC is possible. Additional investigations are necessary to determine the receptor subtypes and/ or heteromers involved in the supraspinal antinociception.
In summary, we found that pretreatment with the NA neurotoxin DSP-4 attenuated the antinociception by i.c.v. a,b-methylene-ATP. Furthermore, intra-LC injection of a ,b-methylene-ATP produced antinociception more potently than i.c.v. administration, and the antinociceptive effect was antagonized by PPADS. These findings suggest that ascending NA neurons arising from the LC are involved in the supraspinal antinociception by a,b-methylene-ATP through P2X receptors in the LC.
